HIP
CRSP icon

HUB Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

HUB Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$352K Buy
7,400
+800
+12% +$42.2K 0.01% 726
2025
Q4 		$346K Buy
6,600
+3,100
+89% +$186K 0.01% 616
2025
Q3 		$227K Buy
3,500
+400
+13% +$23K 0.01% 650
2025
Q2 		$151K Buy
3,100
+1,000
+48% +$38.7K 0.01% 651
2025
Q1 		$71.5K Buy
+2,100
New +$89K ﹤0.01% 602

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HUB Investment Partners's CRSP Position: Q1 2026 in Review

HUB Investment Partners reduced its CRISPR Therapeutics (CRSP) stake by 8.6% in Q1 2026, selling an estimated $14.6K and leaving 2,934 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

HUB Investment Partners first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $295K in Q2 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • HUB Investment Partners held 2,934 shares of CRISPR Therapeutics worth $140K as of Q1 2026.
  • HUB Investment Partners sold 277 CRISPR Therapeutics shares in Q1 2026, an estimated $14.6K.
  • CRISPR Therapeutics made up ﹤0.01% of HUB Investment Partners's portfolio in Q1 2026, its #1036 holding.
  • HUB Investment Partners first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • HUB Investment Partners's CRISPR Therapeutics position peaked at $295K in Q2 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on HUB Investment Partners's 13F filing for Q1 2026, filed 15 May 2026.